Do you give chemotherapy to women with clinical features of high risk ER+ breast cancer, but a low Oncotype DX score?
In a young premenopausal female <35 years old with HR+/HER2-negative T2N0 breast cancer, would Oncotype results influence your decision to offer adjuvant chemotherapy?
Join Mednetto vote and see how they answered.
I wouldn't consider chemotherapy in this patient but some would. I will try to briefly summarize the arguments on both sides.
- Prior to oncotype, we made the decision about chemo based on anatomic risk alone. If the risk of recurrence was predicted to be 10% or greater, guidelines suggested chemoth...
Join for free or sign in to see the full answer
I agree with Dr. @Dr. First Last's response for this T2N0 tumor; what gets more complicated is truly clinical high risk disease such as node-positive. While it is true that few 35 year olds were included in the trial, and estrogen sensitivity differs in pre- and post-menopausal breast cancer, it doe...
Join for free or sign in to see the full answer
I agree with my colleagues above. Genomic tests such as the 21 gene assay appear when low risk to select for disease which has a more benign hormonally driven biology.
The fascinating question in a younger woman is whether the adjustments of the 21 gene assay based on TAILORx (chemo benefit in the 1...
Join for free or sign in to see the full answer
Since she has node-negative disease, I would discuss avoiding chemo if in the low risk range. Would consider ovarian suppression as an alternative if low risk or low intermediate risk.
Join for free or sign in to see the full answer